Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Vintafolide> ?p ?o. }
Showing items 1 to 50 of
50
with 100 items per page.
- Vintafolide abstract "Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is overexpressed on certain cancers, such as ovarian cancer, and a potent chemotherapy drug, vinblastine. It is being developed with a companion imaging agent, etarfolatide, that identifies patients that express the folate receptor and thus would likely respond to the treatment with vintafolide. A Phase 3 study evaluating vintafolide for the treatment of platinum-resistant ovarian cancer (PROCEED trial) and a Phase 2b study(TARGET trial) in non-small-cell lung carcinoma (NSCLC) are ongoing. Vintafolide is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting.A Marketing Authorization Application (MAA) filing for vintafolide and etarfolatide for the treatment of patients with folate receptor-positive platinum-resistant ovarian cancer in combination with doxorubicin, pegylated liposomal doxorubicin (PLD), has been accepted by the European Medicines Agency. The drug received an orphan drug status in Europe in March 2012. Merck & Co. acquired the development and marketing rights to this experimental cancer drug from Endocyte in April 2012. The drug received orphan drug status in Europe in March 2012.[3] Endocyte remains responsible for the development and commercialization of etarfolatide, a non-invasive companion imaging agent used to identify patients expressing the folate receptor that will likely respond to treatment with vintafolide. Vintafolide is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting.".
- Vintafolide atcPrefix "L01".
- Vintafolide atcSuffix "CA06".
- Vintafolide casNumber "742092-03-1".
- Vintafolide iupacName "N-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-(L)-γ-glutamyl-(L)-α-aspartyl-(L)-arginyl-(L)-α-aspartyl-(L)-α-aspartyl-(L)-cysteine disulfide with methyl (5S,7R,9S)-5-ethyl-9-[(3aR,4R,5S,5aR,10bR,13aR)-3a-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-5-({2-[(2-sulfanylethoxy)carbonyl]hydrazinyl}carbonyl)-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl]-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-carboxylate".
- Vintafolide thumbnail Vintafolide.svg?width=300.
- Vintafolide wikiPageID "35530476".
- Vintafolide wikiPageRevisionID "604763373".
- Vintafolide alt "Vintafolide structure".
- Vintafolide atcPrefix "L01".
- Vintafolide atcSuffix "CA06".
- Vintafolide c "86".
- Vintafolide casNumber "742092".
- Vintafolide chemspiderid "27444385".
- Vintafolide h "109".
- Vintafolide hasPhotoCollection Vintafolide.
- Vintafolide iupacName "N--(L)-γ-glutamyl-(L)-α-aspartyl-(L)-arginyl-(L)-α-aspartyl-(L)-α-aspartyl-(L)-cysteine disulfide with methyl -5-ethyl-9-[-3a-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-5--3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl]-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-carboxylate".
- Vintafolide legalStatus "IND".
- Vintafolide molecularWeight "1917".
- Vintafolide n "21".
- Vintafolide o "26".
- Vintafolide s "2".
- Vintafolide smiles "[H]/N=C/NCCC[C@@H]NC[C@H]NCCC[C@@H]NCc1cccNCc1cnc2cc[nH]cN".
- Vintafolide stdinchi "1".
- Vintafolide stdinchikey "KUZYSQSABONDME-QRLOMCMNSA-N".
- Vintafolide synonyms "EC-145".
- Vintafolide width "250".
- Vintafolide subject Category:Experimental_cancer_drugs.
- Vintafolide subject Category:Folates.
- Vintafolide type Agent114778436.
- Vintafolide type Antineoplastic102722458.
- Vintafolide type CausalAgent100007347.
- Vintafolide type CytotoxicDrug103157987.
- Vintafolide type Drug103247620.
- Vintafolide type ExperimentalCancerDrugs.
- Vintafolide type Matter100020827.
- Vintafolide type Medicine103740161.
- Vintafolide type PhysicalEntity100001930.
- Vintafolide type Substance100020090.
- Vintafolide type Drug.
- Vintafolide type FunctionalSubstance.
- Vintafolide comment "Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is overexpressed on certain cancers, such as ovarian cancer, and a potent chemotherapy drug, vinblastine.".
- Vintafolide label "Vintafolide".
- Vintafolide sameAs m.0j9lk9m.
- Vintafolide sameAs Q7932801.
- Vintafolide sameAs Q7932801.
- Vintafolide sameAs Vintafolide.
- Vintafolide wasDerivedFrom Vintafolide?oldid=604763373.
- Vintafolide depiction Vintafolide.svg.
- Vintafolide isPrimaryTopicOf Vintafolide.